APR 17, 2018 08:00 AM PDT

StemoniX microBrain 3D Assay Ready Plates as a Human iPSC-based Neural Spheroid Platform for High Throughput Drug Screening

SPONSORED BY: Molecular Devices
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Lead Scientist Neurosciences at Stemonix
    Biography
      Cassiano Carromeu is the Lead Neuroscientist at StemoniX and an expert in the neuroscience and stem cell biology field. He received his BA in Biomedical Sciences and PhD in Virology from the Universidade Federal de Sao Paulo in Brazil. In 2009, he moved to the USA where he did his post-doctoral training at UC San Diego, using induced Pluripotent Stem Cells (iPSCs) to model autism in vitro. During this time, he helped to unveil some key aspects of Rett Syndrome and MeCP2 Duplication Syndrome. He joined StemoniX in 2016, where he has translated his expertise into products with the goal of facilitating drug discovery in neuroscience. His efforts led to the current microBrain products offered by StemoniX.
    • Senior Product Manager, Cellular Imaging at Molecular Devices, LLC.
      Biography
        Grischa Chandy is the Senior Product Manager for Cellular Imaging at Molecular Devices. Grischa's scientific background is in cell biology, physiology and biophysics. He has used and developed imaging techniques and technologies throughout his career starting with his doctoral work at U.C. Irvine, his postdoc at U.C. Berkeley as well as Research Scientist position at Stanford University. Grischa has been with Molecular Devices for over 10 years, driving launches of the ImageXpress® Micro XL and ImageXpress Micro XLS systems, MetaXpress® Software version 3 onward, and most recently, the launch of the ImageXpress Micro Confocal system.
      • Senior Research Scientist at Molecular Devices,LLC
        Biography
          Oksana Sirenko is a Senior Research Scientist at Molecular Devices working on development of new technologies for imaging and high content analysis. Oksana also has previous experience working on drug discovery and drug development at several biotech companies in San Francisco Bay Area. The focus of her current scientific research is on development methods for high throughput in vitro toxicity screening, including 3D models. Oksana has a PhD in Biochemistry and B.S. in Biology.

        Abstract:

        DATE: April 17, 2018
        TIME: 8:00AM PST, 11:00AM EST

        Recently, much research has focused on obtaining 3D brain organoids to better recapitulate brain development and function in vitro. However, current protocols lead to variable organoid size and function, making the use of these powerful tools impractical in drug screening scenarios.

        Here, we describe StemoniX® microBrain® 3D Assay Ready Plates, highly homogenous human induced Pluripotent Stem Cell (hiPSC)-derived cortical spheroid screening platform in a 384-well format. Each well contains a single uniformly sized spheroid, with a fully developed foundation of cortical neurons and astrocytes co-matured from a single donor source. Immunofluorescence analysis indicates that the neurons and astrocytes display key markers of cellular identity and maturity, such as synaptic proteins and glutamate transporters.

        microBrain cortical spheroids present highly synchronized, quantifiable, robust, and uniform spontaneous calcium oscillations, which can be measured in kinetic high throughput screening (HTS) plate readers, such as the FLIPR Tetra® High-Throughput Cellular Screening System, and, at the cellular level, with high content imaging systems, such as the ImageXpress® Micro Confocal High-Content Imaging System. The calcium signal can be reproducibly modified with excitatory and inhibitory neuromodulators, confirming the presence of a functionally integrated glutamatergic and GABAergic circuitry. For HTS applications, microBrain 3D Assay Ready generates remarkably consistent results, displaying minimal variability across wells and plate replicates. Additionally, these cortical organoids are amenable to immunostaining in suspension, enabling scalable high content image-based assays focused on key protein markers. Delivered to customers pre-plated under ambient conditions, this powerful product can be easily implemented as a reliable HTS platform for drug discovery, safety pharmacology and neurotoxicology, and disease modeling.

        Learning Objectives:
        •    Key characteristics of microBrain 3D Assay Ready spheroids
        •    Applications of microBrain 3D Assay Ready for high throughput drug screening
        •    microBrain 3D Assay Ready is delivered to the customer ready to use, integrating easily into their high throughput           screening platforms


        Show Resources
        You May Also Like
        MAY 22, 2018 08:00 AM PDT
        C.E. CREDITS
        MAY 22, 2018 08:00 AM PDT
        DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
        MAY 24, 2018 09:30 AM PDT
        C.E. CREDITS
        MAY 24, 2018 09:30 AM PDT
        DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
        MAY 03, 2018 11:00 AM PDT
        MAY 03, 2018 11:00 AM PDT
        DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
        APR 27, 2018 10:00 AM PDT
        C.E. CREDITS
        APR 27, 2018 10:00 AM PDT
        DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
        MAY 02, 2018 08:00 AM PDT
        C.E. CREDITS
        MAY 02, 2018 08:00 AM PDT
        Immunohistochemistry protocols, which utilize antibodies to visualize proteins in tissue sections, have many steps that need optimized to prevent non-specific background effects, artifacts, o...
        AUG 15, 2018 08:00 AM PDT
        C.E. CREDITS
        AUG 15, 2018 08:00 AM PDT
        DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
        Loading Comments...
        Show Resources